In:
Clinical Diabetes, American Diabetes Association, Vol. 40, No. 3 ( 2022-07-01), p. 327-338
Abstract:
Nonalcoholic fatty liver disease (NAFLD) is dramatically increasing in parallel with the pandemic of type 2 diabetes. Here, the authors aimed to assess the performance of the most commonly used noninvasive, blood-based biomarkers for liver fibrosis (FibroTest, NAFLD fibrosis score, BARD score, and FIB-4 Index) in subjects with type 2 diabetes. Liver stiffness measurement was estimated by two-dimensional shear wave elastography. Finally, the authors assessed the diagnostic role of ActiTest and NashTest 2 in liver fibrosis in the examined population.
Type of Medium:
Online Resource
ISSN:
0891-8929
,
1945-4953
Language:
English
Publisher:
American Diabetes Association
Publication Date:
2022
detail.hit.zdb_id:
2001527-6
